Study finds FDA warning letters rarely mention AI
A peer-reviewed review of 3,011 FDA warning letters found just seven references to artificial intelligence between January 2022 and September 2026, with the earliest cited use appearing in CDER correspondence. The analysis suggests AI is entering FDA enforcement language, but the small sample does not prove a broader regulatory trend.
Why it matters: - Artificial intelligence is showing up in FDA enforcement correspondence, which matters for how regulators describe quality, compliance and risk. - The study offers a first look at where AI appears in public FDA warning letters across devices, tobacco and drug manufacturing. - The findings may help regulated companies understand how FDA is starting to frame AI-related issues in enforcement language.
What happened: - An independent analysis published October 31, 2026, in the peer-reviewed journal Discover Pharmaceutical Sciences reviewed 3,011 FDA warning letters. - The review covered letters in FDA's public database with issue dates from January 1, 2022, through September 28, 2026. - Seven warning letters, or 0.23%, referred to AI. - Three of the seven letters involved medical devices. - Three involved tobacco products. - One involved drug manufacturing. - The analysis identified the earliest CDER warning letter citing AI use. - The authors were George Kwiecinski and Reet Nandy, who hold leadership roles at KeyPedia. - Their KeyPedia roles are disclosed in the paper.
The details: - The paper examines each of the seven warning letters that mentioned AI. - It identifies where the AI reference appears in each letter. - It explains how the AI reference relates to the product or process under review. - It notes which violations FDA cited in each case. - The distinction helps show whether AI was part of the cited deficiency or part of the surrounding description. - The researchers also documented their search and screening decisions in a supplementary file. - The study separately described one establishment inspection report and two Form FDA 483s that referred to AI. - Those inspection records were analyzed separately because publicly released records do not provide a complete set for calculating frequency.
Between the lines: - The sample is small, so the paper does not establish an enforcement trend. - The analysis covers published correspondence, not how widely regulated firms are actually using AI. - The study does not examine AI in product approvals or software as a medical device. - The findings point to a narrow but concrete regulatory footprint for AI inside FDA enforcement records. - Reet Nandy said: “Every breakthrough in medicine has depended on trust. As AI becomes part of how medicines are made and regulated, our opportunity is to build that trust in the open, with data anyone can examine.”
What's next: - The authors' method creates a baseline for future tracking of AI references in FDA enforcement documents. - Additional correspondence and inspection records will show whether these mentions remain rare or become more common. - Companies that use AI in regulated workflows may face closer scrutiny as FDA language evolves.
The bottom line: - FDA warning letters only rarely mention AI so far, but the first documented CDER reference suggests the agency is beginning to confront the technology in enforcement settings.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
IT Press Releases
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.